Next 10 |
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the C...
2024-04-10 12:03:39 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain Ionis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Ionis Pharmaceuticals, Inc. (IONS) Q4 2023 Earnings Call Transc...
– Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3 – – A Single Dose of Zilebesiran Resulted in Clinically Significant Additiv...
2024-04-03 11:57:45 ET Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward w...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in develo...
– Family Health History Road Trip Program Aims to Inspire Conversations About Health History and Empower Families to Take Control of Their Health – – Genealogist and Health Educator Bernice Bennett Travels Cross-Country to Visit Members of hATTR Amyloidosis Commun...
2024-03-10 00:54:52 ET Summary Alnylam has pushed back the data readout for its HELIOS-B trial from early 2024 to June/July 2024, causing a 10% decline in the stock price. The company has made changes to the study duration, primary endpoint, and secondary endpoints of the trial, r...
2024-03-05 09:57:44 ET More on Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript Alnylam's Huge Opportunity Alnylam posts Q4 topline miss;...
– Study Met the Primary Endpoint Demonstrating Clinically Significant Systolic Blood Pressure Reductions at Month 3 When Zilebesiran Was Added to a Diuretic, Calcium-Channel Blocker or Angiotensin Receptor Blocker – – Zilebesiran Demonstrated an Encouraging Safety and...
2024-02-28 22:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the C...
On Sunday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and...
– Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3 – – A Single Dose of Zilebesiran Resulted in Clinically Significant Additiv...